ArticleStem cell research & therapy2025
Intra-articular delivery of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSCs) for painful lumbar facet arthropathy: a phase I clinical trial.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04410731 (CellKine), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CellKine: Phase I Study Evaluating the Safety and Feasibility of Allogeneic, Culture-Expanded Bone Marrow-Derived Mesenchymal Stem Cells in Subjects with Painful Lumbar Facet Joint Arthropathy
Who cites it
3 citing papers in PubMed.
- Microfragmented Adipose Tissue in Pain Management: Bridging Regenerative Biology and Clinical Therapeutics.Pain and therapy · 2026Review
- Article
- Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
importanceLumbar facet arthropathy (LFA) is one of the most common specific disorders associated with low back pain. Current treatments provide only symptomatic relief and are often limited in their long-term effectiveness.
objectiveTo evaluate the safety and preliminary efficacy of intra-articular delivery of allogeneic BM-MSCs in patients with painful LFA. DESIGN, SETTING, AND
participantsThis study was a prospective, Phase I, single-arm, open-label clinical trial. Ten patients with painful LFA were enrolled with nine completing the 2-year follow-up.
interventionsAll patients received a single intra-articular administration into two affected lumbar facet joints, with each joint injected 10 million allogeneic BM-MSCs suspended in 1 mL Lactated Ringer's solution. MAIN OUTCOMES AND MEASURES: The primary endpoint was safety, as reflected by adverse events (AEs). Secondary endpoints (and the assessment tools) included low back pain (VAS), physical function (PROMIS CAT Physical Function), health status (PROMIS CATs), and the severity of facet joint degeneration on MRIs. The minimum clinically important difference (MCID) thresholds in this trial were pre-defined as a 50% reduction in low back pain (VAS), or an increase of 2.3 points on the PROMIS CAT Physical Function.
resultsThe procedures were well tolerated. There were no clinical signs of immune reaction to the allogeneic BM-MSCs. No study-related serious AEs were observed. Six patients achieved the MCID on VAS for pain at 6-, 12-, 18-, and 24-month follow-ups and five patients consistently met MCID for the PROMIS CAT Physical Function across all follow-up visits. MRIs showed reduced facet joint degeneration at one or more levels in five patients. CONCLUSIONS AND RELEVANCE: This study demonstrated a favorable safety profile for intra-articular delivery of BM-MSCs for painful LFA. Preliminary therapeutic benefits were observed, including back pain relief, improved physical function, and reduced facet joint degeneration. Further larger, randomized clinical trials are warranted to further assess its safety and efficacy. Trial Registration ClinicalTrials.gov Identifier: NCT04410731.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.